Allergan ($AGN) is taking its hashtag-heavy, emoji-laden female empowerment campaign, #ActuallySheCan, to the Tribeca Film Festival. Three women directors created films featuring three women aiming at big goals, including one who's competing in the famed Iditarod sled-dog race. All three will be screened at the New York-based festival. More from FiercePharmaMarketing
@FiercePharma: WHO fights Angola yellow fever outbreak, global vaccine shortage. More from FierceVaccines | Follow @FiercePharma
@EricPFierce: Unable to find a buyer, Sun will close the Ranbaxy plant in Ireland, lay off 70 remaining workers. FiercePharmaManufacturing report | Follow @EricPFierce
@CarlyHFierce: Valeant's prized GI force, once shielded from job cuts, faces the ax. FiercePharmaMarketing story | Follow @CarlyHFierce
> Johnson & Johnson ($JNJ) is eyeing more growth in Africa, and it's adding new R&D and distribution there to beef up sales of new meds to fight HIV and other diseases common on the continent. Report
> Hedge fund billionaire John Paulson may have suffered a $258 million hit on the collapse of the Pfizer-Allergan merger, harking back to previous losses from a bet on the AbbVie-Shire combo, which also failed because of tax-inversion rule changes. Report
> Amphastar Pharmaceuticals ($AMPH), which has come in for criticism for the price of its overdose antidote naloxone, agreed to give Connecticut a $6 rebate for each dose purchased by a state or municipal agency. Report
> The cost of insulin treatments for diabetes rose by nearly 200% from 2002 to 2013, the Journal of the American Medical Association reports, as expensive new analog treatments supplanted older human insulins. Report
> Hedge funder Bill Ackman is set to explain a 25% quarterly loss to his investors Wednesday, with his bad bet on Valeant Pharmaceuticals ($VRX) first in line. Report
Medical Device News
@FierceMedDev: ICYMI yesterday: Warburg-backed Sterigenics buys Nelson Labs to create largest sterilization, testing firm. Article | Follow @FierceMedDev
@EmilyWFierce: ICYMI from FiercePharma: Biogen, Samsung accuse AbbVie of evergreening Humira patents to block biosims. Report | Follow @EmilyWFierce
> Duke University sends recs to FDA for new medical device safety evaluation system. Article
Biotech News
@FierceBiotech: New study highlights a gut pathway for red wine compound resveratrol. More from FierceBiotechResearch | Follow @FierceBiotech
@JohnCFierce: Allergan pivots back to dealmaking as analysts link Pfizer to AbbVie, Biogen and Regeneron. Story | Follow @JohnCFierce
> J&J grabs prostate cancer rights for Tesaro's niraparib in $500M deal. Report
> Apricus wields ax to its pipeline, staff after key testosterone drug fails. Story
> Celltrion, Pfizer win landmark FDA OK for a biosimilar of J&J's blockbuster Remicade. Article
Biotech Research News
> Wistar scientists show impact of aging on melanoma therapy in the lab. Report
> U.S. academics test new mouse model for possible Zika vaccine. More
> Cryoablation therapy used to treat phantom limb pain. Item
> New study highlights a gut pathway for red wine compound resveratrol. Story
> A stem cell therapy trial finally delivers positive results for heart failure. Article
Vaccines News
> Complacency could derail Ebola progress, experts warn. Item
> Experts share info in scramble to fight 'impressive' Zika virus. Report
> WHO fights Angola yellow fever outbreak, global vaccine shortage. Story
> NIAID greenlights funds for adjuvant research. Article
> Genocea reports promising 12-month data for its genital herpes vaccine. More
Pharma Marketing News
> Up up and away: 2015 pharma ad spending ties decade-old record. Item
> Allergan amps up #ActuallySheCan campaign with Tribeca festival film. More
> Boomers are tough on digital pharma ads, but they do like celeb endorsements. Report
> Valeant's prized GI force, once shielded from job cuts, faces the ax. Story
> FDA nitpicks Shiongi's head lice copay voucher over 'false and misleading' claims. Article
And Finally... Worldwide diabetes cases hit 422 million as the disease mushrooms in the developing world. Report